BillionToOne, Inc. vs Quest Diagnostics Inc, two Medical Diagnostics stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where BLLN and DGX diverge most: on ev/ebitda, BLLN reads 127.4 and DGX reads 14.0; on revenue growth, BLLN reads +88.5% and DGX reads +9.9%. The rest of the comparable metrics sit closer together. What DGX's price implies is a bet that sits within the historical range (whole-company basis). The bull and bear cases for each are in their full reports below.
| Metric | BLLN | DGX |
|---|---|---|
| Price | $98.15 | $231.00 |
| Market cap | $5.3B | $25.9B |
| Sector | Medical Diagnostics | Medical Diagnostics |
| Stage | Growth | Mature |
| Implied growth (priced in) | — | -1.1% |
| P/E | 172.2 | 24.5 |
| P/B | 9.96 | 3.31 |
| P/S | 14.53 | 2.24 |
| EV/EBITDA | 127.4 | 14.0 |
| Revenue growth | +88.5% | +9.9% |
| Gross margin | 70.5% | — |
| Operating margin | 5.0% | 15.1% |
| Net margin | 8.6% | 9.2% |
| Return on equity | 5.9% | 13.6% |
| Return on assets | 4.3% | 6.3% |
| Return on invested capital | 4.6% | 9.6% |
| FCF yield | 0.6% | 5.2% |
| Dividend yield | — | 0.8% |
| Debt / equity | 0.17 | 0.72 |
| Current ratio | 11.69 | 1.59 |
| Altman Z (solvency) | 7.03 | 7.70 |
| Piotroski F (quality) | 6 / 9 | 7 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.